Analytical developments of p-hydroxy prenylamine reference material for dope control research: Characterization and purity assessment

被引:10
作者
Joseph, Athira [1 ]
Kumar, Gangasani Jagadeesh [1 ,2 ]
Pawar, Sachin Dattram [1 ]
Hirlekar, Bhakti Umesh [2 ]
Bharatam, Prasad, V [3 ]
Konda, Satyanand [4 ,5 ]
Mudiam, Mohana Krishna Reddy [4 ,5 ]
Murty, Upadhyayula Suryanarayana [1 ]
Sahu, P. L. [6 ]
Dubey, Sachin [6 ]
Radhakrishnanand, P. [1 ]
Adye, Daya Raju [1 ]
Borkar, Roshan M. [1 ]
Thirupathi, Choppari [7 ]
Kumar, Pramod [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharmaceut Anal, PO Changsari, Gauhati 781101, Assam, India
[2] Natl Inst Pharmaceut Educ & Res NIPER, Dept Med Chem, PO Changsari, Gauhati 781101, Assam, India
[3] Natl Inst Pharmaceut Educ & Res NIPER, Dept Med Chem, Sect 67, Mohali 160062, Punjab, India
[4] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India
[5] CSIR Indian Inst Chem Technol, Analyt & Struct Chem Dept, Uppal Rd, Hyderabad 500007, Telangana, India
[6] Natl Dope Testing Lab, JLN Stadium Complex,East Gate 10, New Delhi 110003, India
[7] Daicel Chiral Technol India Private Ltd, IKP Knowledge Pk,Survey 542-2, Hyderabad 500101, Telanagana, India
关键词
chiral R and S separation; HPLC; impurity fragmentation; LC-MS; MS; prenylamine metabolite; AMPHETAMINE;
D O I
10.1002/dta.3171
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Prenylamine was initially used for the treatment of angina pectoris and later on withdrawn from the market in 1988 due to cardiac arrhythmias concern. The major phase I metabolite of prenylamine is p-hydroxy prenylamine that has a chiral center in the structure. Even though p-hydroxy prenylamine was synthesized earlier, it lacked complete analytical developments for chiral high-performance liquid chromatography (HPLC) separation. However, p-hydroxy prenylamine reference material is not commercially available. The innovation of this manuscript is the development and validation of a chiral HPLC separation method and more extensive characterization of the reference material than previously reported method. Therefore, it was hypothesized to develop and validate normal phase HPLC method for p-hydroxy prenylamine reference material. p-Hydroxy prenylamine was synthesized in two batches and characterized successfully using C-13 NMR, H-1 NMR, high-resolution mass spectrometry (HRMS), Fourier transform infrared spectroscopy (FT-IR), and thermogravimetric analysis (TGA). A normal phase chiral HPLC method was developed to analyze the p-hydroxy prenylamine purity. Separation of the p-hydroxy prenylamine enantiomers were achieved using ultra-high-performance liquid chromatography (UHPLC) on a ChiralCel ODH column at wavelength of 220 nm. The developed method was validated in terms of its linearity, accuracy, precision, and robustness for purification, purity assessment, and stability studies. Proton and carbon peaks were confirmed by nuclear magnetic resonance (NMR) analysis. Functional groups were confirmed by FT-IR. Loss on drying was 0.3% and 0.6% for Batches 1 and 2, respectively. The purity of the developed reference material for Batches 1 and 2 was found to be 99.59% and 100%, respectively. Therefore, the synthesized batches of p-hydroxy prenylamine can be used in dope testing as reference material.
引用
收藏
页码:224 / 232
页数:9
相关论文
共 22 条
[1]   Identification and characterization of urinary prenylamine metabolites by means of liquid chromatography-tandem mass spectrometry [J].
Beuck, S. ;
Sigmund, G. ;
Koch, A. ;
Schaenzer, W. ;
Pokrywka, A. ;
Kwiatkowska, D. ;
Thevis, M. .
DRUG TESTING AND ANALYSIS, 2012, 4 (09) :701-716
[2]   Guidelines from the International Conference on Harmonisation (ICH) [J].
Branch, SK .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 38 (05) :798-805
[3]   Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions [J].
Camont, Laurent ;
Cottart, Charles-Henry ;
Rhayem, Yara ;
Nivet-Antoine, Valerie ;
Djelidi, Raja ;
Collin, Fabrice ;
Beaudeux, Jean-Louis ;
Bonnefont-Rousselot, Dominique .
ANALYTICA CHIMICA ACTA, 2009, 634 (01) :121-128
[4]   Medicine and science in the fight against doping in sport [J].
Catlin, D. H. ;
Fitch, K. D. ;
Ljungqvist, A. .
JOURNAL OF INTERNAL MEDICINE, 2008, 264 (02) :99-114
[5]   Development and validation of a stability indicating RP-HPLC-DAD method for the determination of bromazepam [J].
Darwish, Hany W. ;
Ali, Nesma A. ;
Naguib, Ibrahim A. ;
El Ghobashy, Mohamed R. ;
Al-Hossaini, Abdullah M. ;
Abdelrahman, Maha M. .
PLOS ONE, 2021, 16 (03)
[6]   Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls [J].
Dib, Josef ;
Mongongu, Cynthia ;
Buisson, Corinne ;
Molina, Adeline ;
Schaenzer, Wilhelm ;
Thuss, Uwe ;
Thevis, Mario .
DRUG TESTING AND ANALYSIS, 2017, 9 (01) :61-67
[7]   Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) [J].
Docherty, J. R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (03) :606-622
[8]   The effectiveness of the World Anti-Doping Agency: developing a framework for analysis [J].
Houlihan, Barrie ;
Hanstad, Dag Vidar .
INTERNATIONAL JOURNAL OF SPORT POLICY AND POLITICS, 2019, 11 (02) :203-217
[10]   Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine - Studies using fluorescence polarization immunoassay (FPIA) and GC-MS [J].
Kraemer, T ;
Roditis, SK ;
Peters, FT ;
Maurer, HH .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2003, 27 (02) :68-73